← Back to Search

Other

ATI-2231 for Solid Tumor Cancers

Phase 1
Waitlist Available
Led By Cynthia X Ma, M.D., Ph.D.
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline through 30 days after end of treatment (estimated to be 7 months)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called ATI-2231 in patients with serious types of cancer to determine the most effective dose.

Eligible Conditions
  • Solid Tumors
  • Solid Tumor Cancers

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline through 30 days after end of treatment (estimated to be 7 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline through 30 days after end of treatment (estimated to be 7 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants experiencing adverse events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ATI-2231 monotherapy dose escalationExperimental Treatment1 Intervention
* Patients will receive single agent ATI-2231 at assigned dose levels (n=3-6 per dose level). Starting dose of 20 mg by mouth twice per day. * Each cycle is 21 days

Find a Location

Who is running the clinical trial?

United States Department of DefenseFED
916 Previous Clinical Trials
334,717 Total Patients Enrolled
Washington University School of MedicineLead Sponsor
2,000 Previous Clinical Trials
2,344,262 Total Patients Enrolled
Aclaris Therapeutics, Inc.Industry Sponsor
34 Previous Clinical Trials
4,942 Total Patients Enrolled
Cynthia X Ma, M.D., Ph.D.Principal InvestigatorWashington University School of Medicine
3 Previous Clinical Trials
291 Total Patients Enrolled

Media Library

ATI-2231 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05791474 — Phase 1
Solid Tumors Research Study Groups: ATI-2231 monotherapy dose escalation
Solid Tumors Clinical Trial 2023: ATI-2231 Highlights & Side Effects. Trial Name: NCT05791474 — Phase 1
ATI-2231 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05791474 — Phase 1
~0 spots leftby Jun 2025